9 results on '"Katharina Möller"'
Search Results
2. Pathologie und genetische Faktoren des kleinzelligen Lungenkarzinoms
- Author
-
Guido Sauter, Stefan Steurer, Ronald Simon, and Katharina Möller
- Subjects
Gynecology ,medicine.medical_specialty ,Oncology ,business.industry ,Medicine ,Hematology ,business - Abstract
Eine wichtige Entitat der Lungenkarzinome ist das kleinzellige Lungenkarzinom , das aufgrund differenter Therapien von sog. nichtkleinzelligen Karzinomen und anderen blauzelligen Tumoren unterschieden werden muss. Der Schwerpunkt der Arbeit liegt in der Darstellung der typischen histomorphologischen, immunhistochemischen und genetischen Befunde eines kleinzelligen Karzinoms sowie der relevanten Differenzialdiagnosen. Es erfolgte eine Literaturrecherche in der Datenbank PubMed sowie in der gangigen pathologischen Fachliteratur. Eine sichere Diagnosestellung dieser aggressiven Tumorentitat ist von groster Bedeutung, um schnellstmoglich eine adaquate Therapie beginnen zu konnen. Hierfur sind immunhistochemische Untersuchungen unerlasslich. Trotz maximaler Therapie zeigt sich eine eher geringe 5‑Jahres-Uberlebenswahrscheinlichkeit. Neue Immuncheckpointtherapien konnten bei einem Teil der Patienten eine hohe Wirksamkeit haben.
- Published
- 2021
3. Prognostic role of proliferating CD8+ cytotoxic Tcells in human cancers
- Author
-
Anne Menz, Jonas B Raedler, Franziska Büscheck, Cheng Yang, Wenchao Li, Andreas Marx, Waldemar Wilczak, Katharina Möller, Guido Sauter, Stefan Steurer, Christian Bernreuther, Eike Burandt, Christoph Fraune, David Dum, Sarah Minner, Ronald Simon, Hannah L Jansen, Patrick Lebok, Niclas C Blessin, Andreas M. Luebke, Till Krech, Doris Höflmayer, Ria Uhlig, Andrea Hinsch, Tim Mandelkow, and Till S. Clauditz
- Subjects
0301 basic medicine ,Cancer Research ,Tumor microenvironment ,business.industry ,Colorectal cancer ,T cell ,Cancer ,General Medicine ,medicine.disease ,Immune checkpoint ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,Pancreatic cancer ,medicine ,Cancer research ,Molecular Medicine ,Cytotoxic T cell ,Ovarian cancer ,business - Abstract
Purpose Expansion of CD8+ cytotoxic Tlymphocytes is a prerequisite for anti-cancer immune activity and has gained interest in the era of immune checkpoint therapy. Methods To understand the CD8+ T cell dynamics in the tumor microenvironment, we used multiplex fluorescence immunohistochemistry to quantitate CD8+ proliferation (Ki67 co-expression) in tissue microarrays from 1107 colorectal, 642 renal cell, 1066 breast, 375 ovarian, 451 pancreatic and 347 gastric cancer samples. Results The density and the percentage of proliferating (Ki67+) CD8+ T cells were both highly variable between tumor types as well as between patients with the same tumor type. Elevated density and percentage of proliferating CD8+ cytotoxic T cells were significantly associated with favorable tumor parameters such as low tumor stage, negative nodal stage (p ≤ 0.0041 each), prolonged overall survival (p ≤ 0.0028 each) and an inflamed immune phenotype (p = 0.0025) in colorectal cancer and, in contrast, linked to high tumor stage, advanced ISUP/Fuhrman/Thoenes grading (each p ≤ 0.003), shorter overall survival (p ≤ 0.0330 each) and an immune inflamed phenotype (p = 0.0094) in renal cell cancer. In breast, ovarian, pancreatic and gastric cancer the role of (Ki67+)CD8+ Tcells was not linked to clinicopathological data. Conclusion Our data demonstrate a tumor type dependent prognostic impact of proliferating (Ki67+)CD8+ Tcells and an inverse impact in colorectal and renal cell cancer.
- Published
- 2021
4. Elevated MUC5AC expression is associated with mismatch repair deficiency and proximal tumor location but not with cancer progression in colon cancer
- Author
-
Ria Uhlig, Anne Menz, Eike Burandt, Ronald Simon, Michael Neipp, Franziska Büscheck, Daniel Perez, Andrea Hinsch, Patrick Lebok, Albert Goetz, Sebastian Dwertmann Rico, Till Krech, Christoph Fraune, Christina Möller-Koop, Till S. Clauditz, Andreas M. Luebke, Christian Bernreuther, Holger Rupprecht, Christoph Isbert, Claudia Hube-Magg, Martina Kluth, Hannes Lárusson, Jakob R. Izbicki, Hamid Mofid, Guido Sauter, Stefan Steurer, Thies Daniels, Doris Höflmayer, Stephan Coerper, Andreas H. Marx, Katharina Möller, Daniel Ditterich, David Dum, and Waldemar Wilczak
- Subjects
Colorectal cancer ,Mucin 5AC ,DNA Mismatch Repair ,digestive system ,Tissue microarray ,Pathology and Forensic Medicine ,Cecum ,fluids and secretions ,medicine ,Humans ,Molecular Biology ,Aged ,Original Paper ,Progression ,business.industry ,Mucin ,Cancer ,General Medicine ,respiratory system ,MUC5AC ,medicine.disease ,Immunohistochemistry ,Molecular medicine ,Colon cancer ,Gene Expression Regulation, Neoplastic ,medicine.anatomical_structure ,Disease Progression ,Cancer research ,MISMATCH REPAIR DEFICIENCY ,sense organs ,Colorectal Neoplasms ,business ,Mismatch repair deficiency - Abstract
Mucin 5AC (MUC5AC) is a secreted gel-forming mucin expressed by several epithelia. In the colon, MUC5AC is expressed in scattered normal epithelial cells but can be abundant in colorectal cancers. To clarify the relationship of MUC5AC expression with parameters of tumor aggressiveness and mismatch repair deficiency (dMMR) in colorectal cancer, a tissue microarray containing 1812 colorectal cancers was analyzed by immunohistochemistry. MUC5AC expression was found in 261 (15.7%) of 1,667 analyzable colorectal cancers. MUC5AC expression strongly depended on the tumor location and gradually decreased from proximal (27.4% of cecum cancers) to distal (10.6% of rectal cancers; p p p
- Published
- 2020
5. Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions
- Author
-
Hans Heinzer, Sarah Minner, Markus Graefen, Doris Höflmayer, Sebastian Dwertmann Rico, Maria Christina Tsourlakis, Christoph Fraune, Claudia Hube-Magg, Jan Meiners, Christian Bernreuther, Till Eichenauer, Eike Burandt, Stefan Steurer, Ferdous Daghigh, Alexander Haese, Thorsten Schlomm, Katharina Möller, Guido Sauter, Jakob R. Izbicki, Andreas M. Luebke, David Dum, Maximilian Lennartz, Hartwig Huland, Christina Möller-Koop, Ronald Simon, Till S. Clauditz, Corinna Wittmer, and Florian Lutz
- Subjects
Male ,Cancer Research ,Oncogene Proteins, Fusion ,TMPRSS2 ,Pathology and Forensic Medicine ,Transcriptional Regulator ERG ,Prostate ,Proto-Oncogene Proteins ,Biomarkers, Tumor ,medicine ,Humans ,TMA ,Aged ,Prostatectomy ,Prostate cancer ,Tissue microarray ,business.industry ,Serine Endopeptidases ,Prostatic Neoplasms ,Cancer ,General Medicine ,Middle Aged ,Prostate-Specific Antigen ,Prognosis ,medicine.disease ,Survival Rate ,medicine.anatomical_structure ,Oncology ,Tissue Array Analysis ,Case-Control Studies ,Cancer research ,Immunohistochemistry ,Original Article ,SFRP4 ,business ,Erg ,Immunostaining ,Follow-Up Studies - Abstract
Secreted frizzled-related protein 4 (SFRP4) controls WNT signaling and is thought to play a role for tumor aggressiveness. Here, we analyzed a tissue microarray containing 11,152 prostate cancers with pathological, clinical and molecular data by immunohistochemistry. SFRP4 expression was higher in cancer than in non-neoplastic acinar cells. SFRP4 staining was seen in 64.9% of tumors and classified as weak in 33.2%, moderate in 23.9% and strong in 7.8% of cancers. SFRP4 overexpression was linked to advanced tumor stage, high classical/quantitative Gleason grade (p
- Published
- 2020
6. Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers
- Author
-
Stefan Steurer, Ronald Simon, Thorsten Schlomm, Anna Lena Wecker, Martina Kluth, Andreas M. Luebke, Doris Höflmayer, Sarah Minner, Hartwig Huland, Christoph Fraune, Hans Heinzer, Sören Weidemann, Andreas Marx, Waldemar Wilczak, Alexander Haese, Till S. Clauditz, Claudia Hube-Magg, Guido Sauter, Katharina Möller, Georgia Makrypidi-Fraune, Sarah Bonk, and Christian Bernreuther
- Subjects
Male ,0301 basic medicine ,hnRNPA1 ,Heterogeneous nuclear ribonucleoprotein ,Oncogene Proteins, Fusion ,Heterogeneous Nuclear Ribonucleoprotein A1 ,Fusion gene ,Prostate cancer ,0302 clinical medicine ,Risk Factors ,Prostate ,Tissue microarray ,Margins of Excision ,General Medicine ,Middle Aged ,Prognosis ,Immunohistochemistry ,Up-Regulation ,Treatment Outcome ,medicine.anatomical_structure ,Lymphatic Metastasis ,030220 oncology & carcinogenesis ,Original Article ,Kallikreins ,Gene Fusion ,Biochemical recurrence ,TMPRSS2 ,Pathology and Forensic Medicine ,03 medical and health sciences ,Predictive Value of Tests ,Biomarkers, Tumor ,medicine ,Humans ,TMA ,Molecular Biology ,Aged ,Cell Proliferation ,Neoplasm Staging ,Prostatectomy ,business.industry ,Prostatic Neoplasms ,Cell Biology ,Prostate-Specific Antigen ,medicine.disease ,030104 developmental biology ,Tissue Array Analysis ,Cancer cell ,Cancer research ,Neoplasm Grading ,Neoplasm Recurrence, Local ,business - Abstract
Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) is a ubiquitous RNA splicing factor that is overexpressed and prognostically relevant in various human cancer types. To study the impact of hnRNPA1 expression in prostate cancer, we analyzed a tissue microarray containing 17,747 clinical prostate cancer specimens by immunohistochemistry. hnRNPA1 was expressed in normal prostate glandular cells but often overexpressed in cancer cells. hnRNPA1 immunostaining was interpretable in 14,258 cancers and considered strong in 33.4%, moderate in 45.9%, weak in 15.3%, and negative in 5.4%. Moderate to strong hnRNPA1 immunostaining was strongly linked to adverse tumor features including high classical and quantitative Gleason score, lymph node metastasis, advanced tumor stage, positive surgical margin, and early biochemical recurrence (p
- Published
- 2020
7. Prevalence of CD8+ cytotoxic lymphocytes in human neoplasms
- Author
-
Florian Lutz, Tim Mandelkow, Wilfried Fehrle, Christoph Fraune, Patrick Lebok, Eike Burandt, Guido Sauter, Vera Nickelsen, J. R. Izbicki, Andreas M. Luebke, Patrick Spriestersbach, Sören Weidemann, Stefan Steurer, David Dum, Waldemar Wilczak, Niclas C Blessin, Maximillian Lennartz, Franziska Büscheck, Cosima Göbel, Wenchao Li, Florian Viehweger, Katharina Möller, Andrea Hinsch, Ronald Simon, Doris Höflmayer, Till S. Clauditz, Frank Jacobsen, Claudia Hube-Magg, and Sarah Minner
- Subjects
0301 basic medicine ,Cancer Research ,Cytotoxic T cells ,CD8-Positive T-Lymphocytes ,Article ,Tissue microarray ,Lymphocytic infiltrate ,03 medical and health sciences ,Lymphocytes, Tumor-Infiltrating ,0302 clinical medicine ,Neoplasms ,medicine ,Adenocarcinoma of the lung ,Humans ,Lymphocyte Count ,Anaplastic thyroid cancer ,Merkel cell carcinoma ,Tumor-infiltrating lymphocytes ,business.industry ,Melanoma ,Cancer ,General Medicine ,medicine.disease ,Immune checkpoint ,Lymphoma ,030104 developmental biology ,Oncology ,Tissue Array Analysis ,030220 oncology & carcinogenesis ,Cancer research ,Molecular Medicine ,business - Abstract
Purpose Immune checkpoint inhibitors have recently been approved by the US FDA as first and/or second line therapy in a subset of cancer types. Recent evidence suggests that the quantity of tumor infiltrating lymphocytes (TILs) influences the likelihood of response to immune checkpoint inhibitors. Here, we set out to assess the density of CD8+ lymphocytes in a wide range of different cancer types and subtypes. Methods The density of CD8+ lymphocytes was compared across different cancer types using tissue microarrays (TMAs) composed of up to 50 tumor samples each from 84 different cancer types and subtypes. In total 2652 cancers and 608 normal tissues were successfully analyzed by CD8 immunohistochemistry followed by automated image analysis of digitized slides. Results We found that the median CD8+ lymphocyte counts ranged from 6 cells/mm2 in pleomorphic adenoma up to 1573 cells/mm2 in Hodgkin’s lymphoma. The CD8 counts were generally lower in normal tissues compared to cancer tissues. Blood vessels of the spleen were the only non-lymphatic tissue staining positive for CD8. Tumor types approved for checkpoint inhibitor therapy, including malignant melanoma (81), muscle invasive urothelial carcinoma (119), small cell lung cancer (120), clear cell renal cell cancer (153), squamous cell carcinoma (189) and adenocarcinoma of the lung (328) as well as Hodgkin’s lymphoma (1573) were all ranking among the upper half of our list. Comparably high CD8 densities (median cells/mm2) were also found in several rare and aggressive cancer types including Merkel cell carcinoma (70), angiosarcoma (95), anaplastic thyroid cancer (156) and embryonal carcinoma of the testis (186). In 73 of the 84 analyzed cancer types, the highly variable CD8 counts occasionally exceeded the average CD8 count of tumors for which checkpoint inhibitors have been approved. Conclusion These data support the concept that among most tumor types at least some individual cancers may benefit from treatment with immune checkpoint inhibitors.
- Published
- 2020
8. Epithelial splicing regulatory protein 1 and 2 (ESRP1 and ESRP2) upregulation predicts poor prognosis in prostate cancer
- Author
-
Katharina Möller, Claudia Hube-Magg, Morton Freytag, Ria Uhlig, Sarah Minner, Georgia Makrypidi-Fraune, Thorsten Schlomm, Christian Bernreuther, Doris Höflmayer, Corinna Wittmer, Andreas M. Luebke, Hartwig Huland, Ronald Simon, Andrea Hinsch, Hans Heinzer, Elena Bady, Markus Graefen, Maria Christina Tsourlakis, Guido Sauter, Martina Kluth, Sören Weidemann, and David Dum
- Subjects
Male ,0301 basic medicine ,Biochemical recurrence ,Cancer Research ,lcsh:RC254-282 ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Surgical oncology ,Biomarkers, Tumor ,Genetics ,Humans ,Medicine ,Nuclear protein ,Aged ,Prostatectomy ,Tissue microarray ,business.industry ,Alternative splicing ,Prostatic Neoplasms ,RNA-Binding Proteins ,Cancer ,Middle Aged ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Prognosis ,medicine.disease ,Survival Rate ,Epithelial Splicing Regulatory Protein 1 ,030104 developmental biology ,Oncology ,Case-Control Studies ,030220 oncology & carcinogenesis ,Cancer research ,ESRP2 ,Tissue micro array ,business ,ESRP1 ,Research Article ,Follow-Up Studies - Abstract
Background Epithelial splicing regulatory protein 1 (ESRP1) and 2 (ESRP2) regulate alternative splicing events of various pre-mRNAs. Some of these targets play a role in cancer-associated processes, including cytoskeleton reorganization and DNA-repair processes. This study was undertaken to estimate the impact of ESRP1 and ESRP2 alterations on prostate cancer patient prognosis. Methods A tissue microarray made from 17,747 individual cancer samples with comprehensive, pathological, clinical and molecular data was analyzed by immunohistochemistry for ESRP1 and ESRP2. Results Nuclear staining for ESRP1 was seen in 38.6% (36.0% low, 2.6% high) of 12,140 interpretable cancers and in 41.9% (36.4% low, 5.3% high) of 12,962 interpretable cancers for ESRP2. Nuclear protein expression was linked to advanced tumor stage, high Gleason score, presence of lymph node metastasis, early biochemical recurrence, and ERG-positive cancers (p Conclusions Our data show a striking link between nuclear ESRP expression and adverse features in prostate cancer and identifies expression of ESRP1 and/or ESRP2 as independent prognostic markers with a potential for routine application.
- Published
- 2020
9. National and Transnational Labour Markets in European Archaeology
- Author
-
Katharina Möller
- Subjects
Cultural heritage ,Archeology ,Geography ,Economy ,Workforce ,Nationality ,Archaeology - Abstract
The EU-funded project “Discovering the Archaeologists of Europe 2014” (DISCO 2012–2014) has recently gathered data about the archaeological labour market in 21 European countries. A set of core questions was included in the national surveys, and one of these questions regarded the nationality of the archaeological workforce. As a result, it has become obvious that the archaeological labour market is a national market in some countries whereas it is a transnational one in others. This paper will examine the reasons behind this development through three case studies.
- Published
- 2014
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.